Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy

Taylor, David; Meader, Nick; Bird, Victoria; Pilling, Steve; Creed, Francis; Goldberg, David

doi:10.1192/bjp.bp.110.077610

Cited by 69 publications

(40 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drugs that inhibit FAAH activity prolong and enhance the effects of these endogenous CB 1 and PPAR-α ligands when and where they are produced, and might therefore be better tolerated than exogenous ligands such as THC (Piomelli et al, 2006). This general strategy has been applied successfully, for example, with medications that increase endogenous levels of other neurotransmitters such as serotonin (Taylor et al, 2011) and dopamine (Godfrey, 2009).…”

Section: Introductionmentioning

confidence: 99%

Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse

Justinová

Panlilio

Moreno-Sanz

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

Inhibition of the enzyme fatty acid amide hydrolase (FAAH) counteracts reward-related effects of nicotine in rats, but it has not been tested for this purpose in non-human primates. Therefore, we studied the effects of the first-and second-generation O-arylcarbamatebased FAAH inhibitors, URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester) and URB694 (6-hydroxy-[1,1'-biphenyl]-3-ylcyclohexylcarbamate), in squirrel monkeys. Both FAAH inhibitors: (1) blocked FAAH activity in brain and liver, increasing levels of endogenous ligands for cannabinoid and α-type peroxisome proliferator-activated (PPAR-α) receptors; (2) shifted nicotine self-administration dose-response functions in a manner consistent with reduced nicotine reward; (3) blocked reinstatement of nicotine seeking induced by reexposure to either nicotine priming or nicotine-associated cues; and (4) had no effect on cocaine or food self-administration. The effects of FAAH inhibition on nicotine self-administration and nicotine priming-induced reinstatement were reversed by the PPAR-α antagonist, MK886. Unlike URB597, which was not self-administered by monkeys in an earlier study, URB694 was self-administered at a moderate rate. URB694 self-administration was blocked by pretreatment with an antagonist for either PPAR-α (MK886) or cannabinoid CB 1 receptors (rimonabant). In additional experiments in rats, URB694 was devoid of THC-like or nicotine-like interoceptive effects under drug-discrimination procedures, and neither of the FAAH inhibitors induced dopamine release in the nucleus accumbens shell-consistent with their lack of robust reinforcing effects in monkeys. Overall, both URB597 and URB694 show promise for the initialization and maintenance of smoking cessation because of their ability to block the rewarding effects of nicotine and prevent nicotine priming-induced and cue-induced reinstatement.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse

Justinová

Panlilio

Moreno-Sanz

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Depression, in view of its clinical implications in the prognosis of medical disorders regardless of its actual severity, has been equated to ‘bad cholesterol' and the use of antidepressant drugs to statins, which should not be refused to anyone as a preventive or treatment measure - well beyond their original indications [197]. While antidepressant drugs were found to be effective for treating major depression in the setting of medical disease [198,199], their actions on improving medical outcomes have not been demonstrated [200,201] and may rather involve side effects, interactions, and the likelihood of developing iatrogenic comorbidity [118,190,197,202]. …”

Section: Integration Of Psychological Care Into Medical Treatmentmentioning

confidence: 99%

Current Psychosomatic Practice

Fava

Cosci²,

Sonino³

2016

Psychother Psychosom

227

303

View full text Add to dashboard Cite

Psychosomatic research has advanced over the past decades in dealing with complex biopsychosocial phenomena and may provide new effective modalities of patient care. Among psychosocial variables affecting individual vulnerability, course, and outcome of any medical disease, the role of chronic stress (allostatic load/overload) has emerged as a crucial factor. Assessment strategies include the Diagnostic Criteria for Psychosomatic Research. They are presented here in an updated version based on insights derived from studies carried out so far and encompass allostatic overload, type A behavior, alexithymia, the spectrum of maladaptive illness behavior, demoralization, irritable mood, and somatic symptoms secondary to a psychiatric disorder. Macroanalysis is a helpful tool for identifying the relationships between biological and psychosocial variables and the individual targets for medical intervention. The personalized and holistic approach to the patient includes integration of medical and psychological therapies in all phases of illness. In this respect, the development of a new psychotherapeutic modality, Well-Being Therapy, seems to be promising. The growth of subspecialties, such as psychooncology and psychodermatology, drives towards the multidisciplinary organization of health care to overcome artificial boundaries. There have been major transformations in health care needs in the past decades. From psychosomatic medicine, a land of innovative hypotheses and trends, many indications for changes in the current practice of medicine are now at hand. The aim of this critical review is to outline current and potential clinical applications of psychosomatic methods.

show abstract

“…Whether an attempt was made to pool results across indications and whether potential variation in treatment effects between different indications was assessed. Pooled across different indications without considering between-indication variation 21 (40) Pooled across indications for some outcomes (eg, adverse events) but not for the others (eg, effectiveness outcomes) 4 (8) Quantitatively examined variation/heterogeneity between indications with or without pooling across indications 11 (21) No pooling across different indications and no assessment of variation/heterogeneity between indications (quantitative results reported/displayed separately for each study/indication)…”

Section: Data Extraction and Synthesismentioning

confidence: 99%

“…Conditions can also be included to test the hypothesis that effects differ according to theoretical construct, for example, clean vs. contaminated surgery in the aforementioned example. Likewise, the effects of antidepressants and cognitive behavior therapy have been compared across a range of conditions expressly to explore the theory that their effects are linked through a common pathway [21,22].…”

Section: Deciding What Indications To Includementioning

confidence: 99%

Scientific hypotheses can be tested by comparing the effects of one treatment over many diseases in a systematic review

Chen

Hemming

Chilton

et al. 2014

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

show abstract

Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy

Cited by 69 publications

References 90 publications

Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse

Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse

Current Psychosomatic Practice

Scientific hypotheses can be tested by comparing the effects of one treatment over many diseases in a systematic review

Contact Info

Product

Resources

About